-
New sub-analysis data highlights the benefit of LIXIANA®▼ (edoxaban) over warfarin in NVAF patients according to more comprehensive stroke risk scoringDaiichi Sankyo2020-08-03 09:39:52New sub-analysis data highlights the benefit of LIXIANA®▼ (edoxaban) over warfarin in NVAF patients according
-
Zymeworks and Daiichi Sankyo Announce Successful Achievement of a Research Milestone in Bispecific Antibody CollaborationDaiichi Sankyo2021-12-13 15:12:16Zymeworks and Daiichi Sankyo Announce Successful Achievement of a Research Milestone in Bispecific Antibody
-
CHMP Issues a Positive Opinion for Daiichi Sankyo’s Once-Daily LIXIANA® (edoxaban) in Patients with Atrial Fibrillation Undergoing CardioversionDaiichi Sankyo2020-08-03 09:40:24CHMP Issues a Positive Opinion for Daiichi Sankyo’s Once-Daily LIXIANA® (edoxaban) in Patients with Atrial
-
Daiichi Sankyo, Max Planck Innovation and Lead Discovery Center Announce Cancer Research CollaborationDaiichi Sankyo2019-12-11 09:57:57Daiichi Sankyo, Max Planck Innovation and Lead Discovery Center Announce Cancer Research Collaboration
-
Daiichi Sankyo Announces New Analyses of Once-Daily LIXIANA® (edoxaban) to be Presented at the ISTH 2017 CongressDaiichi Sankyo2020-08-03 09:40:52Daiichi Sankyo Announces New Analyses of Once-Daily LIXIANA® (edoxaban) to be Presented at the ISTH 2017
-
New Precision Medicine Data on DS-8201 in HER2-Expressing Breast Cancer Revealed at 2017 American Society of Clinical Oncology (ASCO) Annual MeetingDaiichi Sankyo2017-08-14 17:45:01New Precision Medicine Data on DS-8201 in HER2-Expressing Breast Cancer Revealed at 2017 American Society of
-
Daiichi Sankyo Cancer Enterprise Pipeline Data Showing Swift Progress in Precision Medicine for Breast Cancer to be Presented at 2017 American Society of Clinical Oncology (ASCO) Annual MeetingDaiichi Sankyo2017-12-15 10:32:06Daiichi Sankyo Cancer Enterprise Pipeline Data Showing Swift Progress in Precision Medicine for Breast Cancer
-
Daiichi Sankyo Initiates ENVISAGE-TAVI AF Study Investigating Once-Daily LIXIANA® (edoxaban) in Patients with Atrial Fibrillation Undergoing Transcatheter Aortic Valve ImplantationDaiichi Sankyo2017-07-31 14:05:47Daiichi Sankyo Initiates ENVISAGE-TAVI AF Study Investigating Once-Daily LIXIANA® (edoxaban) in Patients with
-
Daiichi Sankyo Announces 15 Billion Yen Manufacturing Investment to Support Acceleration of Antibody Drug Conjugate PortfolioDaiichi Sankyo2017-08-14 17:45:01Daiichi Sankyo Announces 15 Billion Yen Manufacturing Investment to Support Acceleration of Antibody Drug
-
Daiichi Sankyo Initiates ELIMINATE-AF Study Investigating Once-Daily Lixiana® (edoxaban) in Patients Undergoing Catheter Ablation of Non-valvular Atrial FibrillationDaiichi Sankyo2020-08-03 09:41:20Daiichi Sankyo Initiates ELIMINATE-AF Study Investigating Once-Daily Lixiana® (edoxaban) in Patients
